Biotech Values

[DewDiligence]

Re: Shark vs Bark:

>> Both are in phase II and Squalamine just finished, Combretastatin expected sometime at the end of this year.
<<

OXGN/Hopkins may still be recruiting patients for their phase ½ trial in AMD, so we are clearly ahead of them: http://www.oxigene.com/press/pressreleases.asp

>> …these molecule not only block neovascularization, but also show some positive change on the established disease. I am quite sure, in the long term that Macugen and Lucentis will not be able to show major improvement. <<

Please explain your reasoning!